Vaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025

Core Points - Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant pill vaccines using its proprietary delivery platform [1][3] - The company will present at the H.C. Wainwright Global Investment Conference from September 8-10, 2025, with a specific presentation scheduled for September 8 at 12:00 PM ET [1][2] Company Overview - Vaxart's vaccines are designed to be administered in pill form, which can be stored and shipped without refrigeration, thus eliminating the risk of needle-stick injuries [3] - The company is developing oral vaccines for various diseases, including coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV) [3] - Vaxart has filed broad domestic and international patent applications for its proprietary technology related to oral vaccination using adenovirus and TLR3 agonists [3]